Why the study?
Due to the development of novel pandemic strains, additional antiviral drugs targeting different viral proteins such as the influenza polymerase PA-PB1 subunit interaction are still needed.
Optimization of a peptide-based inhibitor of the influenza PA-PB1 interaction improved solubility and intracellular delivery, providing structural insights and enhanced inhibition in cell-based assays.
Supports preclinical peptide optimization for influenza; leaves open clinical translation pending in vivo and human studies.
Influenza virus causes severe respiratory infection in humans. Current antivirotics target three key proteins in the viral life cycle: neuraminidase, the M2 channel and the endonuclease domain of RNA-dependent-RNA polymerase. Due to the development of novel pandemic strains, additional antiviral drugs targetting different viral proteins are still needed. The protein-protein interaction between polymerase subunits PA and PB1 is one such possible target. We recently identified a modified decapeptide derived from the N-terminus of the PB1 subunit with high affinity for the C-terminal part of the PA subunit. Here, we optimized its amino acid hotspots to maintain the inhibitory potency and greatly increase peptide solubility. This allowed thermodynamic characterization of peptide binding to PA. Solving the X-ray structure of the peptide-PA complex provided structural insights into the interaction. Additionally, we optimized intracellular delivery of the peptide using a bicyclic strategy that led to improved inhibition in cell-based assays.
No takes yet. Share an insight, caveat, or question.
Radilová et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: